[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@ThomasFiligrane Thomas Philippart
Thomas Philippart posts on X about $huma, huma, $60m, dip the most. They currently have XXX followers and XXX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX +73%
- X Month XXXXX +79%
- X Months XXXXXX +293%
- X Year XXXXXX +7,183%
Mentions: X #
- X Week X +33%
- X Month X -XX%
- X Months XX +97%
- X Year XX +1,780%
Followers: XXX #
- X Week XXX no change
- X Month XXX -XXXX%
- X Months XXX +59%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence cryptocurrencies finance
Social topic influence $huma #12, huma, $60m #14, dip, upside, stocks, signals, $fms, investment
Top assets mentioned Huma Finance (HUMA) Fresenius Medical Care AG & Co. KGaA (FMS)
Top Social Posts #
Top posts by engagements in the last XX hours
"-33% I guess I bought the dip 😳 PT: $X after Q4 🚀 $HUMA (Humacyte)"
X Link @ThomasFiligrane 2025-10-07T18:31Z XXX followers, 1336 engagements
"🚨BTIG maintains $HUMA at BUY trimming target to $X (from $7). Thats still a +255 % upside from todays $XXXX level. 📈🫣 BTIG Analyst Ryan Zimmerman remains bullish on Humacytes bioengineered vessel (ATEV) platform a first-in-class regenerative medicine tech despite dilution from the recent $60M raise. #HUMA #biotech #investing #stocks #regenerativemedicine"
X Link @ThomasFiligrane 2025-10-13T16:18Z XXX followers, 1552 engagements
"🚨 $HUMA raises $60M in an oversubscribed direct offering 🚨 Humacyte priced 28.4M shares + warrants at $XXXX each bringing in $60M gross proceeds. Warrants exercisable in XXX days expiring 2031. ✅ Positives: Strong investor demand (oversubscribed) signals confidence. Adds cash runway to advance ATEV commercialization & clinical programs. Extends flexibility ahead of further trauma & dialysis launches. ⚠ Watch-outs: Dilution risk for existing shareholders (28M new shares + future warrant exercises). Short-term price pressure likely as market digests the offering. 🔎 Mid/Long-term: If funds"
X Link @ThomasFiligrane 2025-10-07T13:09Z XXX followers, 2142 engagements
"🚨 WHEN A GLOBAL LEADER HIGHLIGHTS $HUMA IN ITS REPORT Fresenius Medical Care ($FMS) the worlds dialysis giant mentioned Humacyte in its Q2 2025 earnings presentation. 👉 The positive impact of the Humacyte remeasurement is clearly highlighted in their investor slides. 💡 Translation: - They hold $HUMA and are keeping their position. - They are publicly valuing this partnership/investment. - This isnt just an accounting line its a signal of confidence in the companys potential. 📊 When a global leader talks about you in their earnings its never by accident. $FMS $HUMA"
X Link @ThomasFiligrane 2025-08-10T19:27Z XXX followers, 2553 engagements